# Protalix BioTherapeutics, Inc.

**PLX**

NYSE; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001006281

**D/E**

**on the D/E boundary of 305 graded peers in healthcare**

rank 241 of 305; percentile 78.9; sampling error 2.8 points; lower is stronger




**D/E, the sloth**



| Scoreboard | |
|---|---|
| **Profitability** | D<br>percentile 70.4 |
| **Solvency** | D<br>percentile 64.7 |
| **Growth and financing** | C<br>percentile 42.9 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $82.3M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 8 of 13 |
| **Graded from** | filings received through Mar 18, 2026<br>244 days before the rescan; latest periodic filing 10-Q received Nov 10, 2026 |
| **Last close** | $3.03<br>2026-11-16; market equity $255.5M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 18, 2026*

We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. ProCellEx®, our unique, proprietary plant cell-based protein expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Our corporate strategy includes development of treatments for rare and orphan diseases.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 70.4** | | | | | | |
| Gross profitability | 31.3% | 32.8% | | 48.7 | 346 | 2025-12-31 |
| Return on invested capital | not computable | 9.6% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | 6.9% | (6.7%) | 90.3 | 756 | 2025-12-31 |
| Gross margin stability, five years | 5.3 pts | 2.8 pts | 72.0 | 237 | 2025-12-31 |
| **Solvency, sleeve percentile 64.7** | | | | | |
| Altman Z double-prime | (11.01) | 0.31 | 65.3 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (3.61x) | | | |
| *latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 2.51x | 2.68x | 64.1 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 42.9** | | | | | |
| Revenue growth, three-year compound | 3.5% | 9.6% | 63.2 | 400 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 33.9% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | 13.9% | 3.2% | 27.0 | 663 | 2025-12-31 |
| Net share issuance, one year | 3.3% | 1.6% | 38.5 | 624 | 2026-03-01 |

## Among 305 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 236 | Baxter International Inc. (BAX) | 77.3 | D/E | |
| 237 | Cytosorbents Corp. (CTSO) | 77.6 | D/E | short runway, fortress balance sheet |
| 238 | biote Corp. (BTMD) | 78.0 | D/E | |
| 239 | Abeona Therapeutics Inc. (ABEO) | 78.3 | D/E | fortress balance sheet |
| 240 | Quest Diagnostics Inc. (DGX) | 78.6 | D/E | |
| 241 | Protalix BioTherapeutics, Inc. (PLX) | 78.9 | D/E | |
| 242 | Milestone Scientific Inc. (MLSS) | 79.3 | D/E | late filer |
| 243 | Femasys Inc. (FEMY) | 79.6 | D/E | dilution |
| 244 | Ironwood Pharmaceuticals Inc. (IRWD) | 79.9 | D/E | late filer, fortress balance sheet |
| 245 | Gilead Sciences, Inc. (GILD) | 80.3 | D/E | |
| 246 | Vir Biotechnology, Inc. (VIR) | 80.6 | D/E | |

## What the price implies

*at the 2026-11-16 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 16.5% | (1.7%) | 59 |
| Distance from 52-week high | (3.8%) | (31.5%) | 85 |
| EBIT to enterprise value | not computable | 0.5% | |
| Free cash flow yield | (5.3%) | 0.5% | 33 |
| Book value to price | 0.32 | 0.28 | 53 |
| Sales to price | 0.21 | 0.36 | 33 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Composite equity issuance, five years | 61.9% | 13.2% | 76 |
| Relative strength against the sector, log excess return | (0.02) | (0.19) | 59 |
| Twelve-month failure probability, CHS model | not computable | 0.06% | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $22.0M |
| Operating cash flow, four quarters | $17.6M |
| Months of runway | not finite |
| Days since last periodic filing | 7 (10-Q received Nov 10, 2026) |
| Median daily dollar volume, 63 sessions | $2.1M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:Revenues | $52.7M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 2 | cost of revenue | us-gaap:CostOfRevenue | $27.0M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 3 | assets | us-gaap:Assets | $82.3M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 4 | net income | us-gaap:NetIncomeLoss | -$6.6M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$12.0M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 6 | assets | us-gaap:Assets | $73.4M | 2024-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 7 | revenue | us-gaap:Revenues | $53.4M | 2024-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 8 | cost of revenue | us-gaap:CostOfRevenue | $24.3M | 2024-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 9 | revenue | us-gaap:Revenues | $65.5M | 2023-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 10 | cost of revenue | us-gaap:CostOfRevenue | $23.0M | 2023-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 11 | revenue | us-gaap:Revenues | $47.6M | 2022-12-31 | 2025-03-17 | 10-K | 25-003039 |
| 12 | cost of revenue | us-gaap:CostOfRevenue | $19.6M | 2022-12-31 | 2025-03-17 | 10-K | 25-003039 |
| 13 | revenue | us-gaap:Revenues | $38.4M | 2021-12-31 | 2024-03-14 | 10-K | 24-003161 |
| 14 | cost of revenue | us-gaap:CostOfRevenue | $16.3M | 2021-12-31 | 2024-03-14 | 10-K | 24-003161 |
| 15 | current assets | us-gaap:AssetsCurrent | $66.7M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $26.5M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$385.0M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | -$5.5M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 19 | book equity | us-gaap:StockholdersEquity | $48.2M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 20 | liabilities | us-gaap:Liabilities | $34.1M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 21 | operating income | us-gaap:OperatingIncomeLoss | -$23.7M | 2015-12-31 | 2018-03-06 | 10-K | 18-013053 |
| 22 | interest expense | us-gaap:InterestExpense | $3.5M | 2015-12-31 | 2016-03-08 | 10-K | 16-086642 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.6M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $8.7M | 2024-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.3M | 2024-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$1.3M | 2023-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.1M | 2023-12-31 | 2026-03-18 | 10-K | 26-029858 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$25.0M | 2022-12-31 | 2025-03-17 | 10-K | 25-003039 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $628,000 | 2022-12-31 | 2025-03-17 | 10-K | 25-003039 |
| 30 | depreciation amortization | us-gaap:Depreciation | $1.5M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 31 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$5.6M | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 32 | income tax | us-gaap:IncomeTaxExpenseBenefit | $996,000 | 2025-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 33 | current assets | us-gaap:AssetsCurrent | $60.1M | 2024-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 34 | current liabilities | us-gaap:LiabilitiesCurrent | $25.6M | 2024-12-31 | 2026-03-18 | 10-K | 26-029858 |
| 35 | assets | us-gaap:Assets | $84.4M | 2023-12-31 | 2025-03-17 | 10-K | 25-003039 |
| 36 | assets | us-gaap:Assets | $55.8M | 2022-12-31 | 2024-03-14 | 10-K | 24-003161 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 80,571,642 | 2026-03-01 | 2026-03-18 | 10-K | 26-029858 |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 78,032,585 | 2025-03-14 | 2025-03-17 | 10-K | 25-003039 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.